David J McConkey Selected Research

delta-Crystallins

1/2009

Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David J McConkey Research Topics

Disease

109	Neoplasms (Cancer) 01/2024 - 01/2002
66	Urinary Bladder Neoplasms (Bladder Cancer) 02/2024 - 07/2003
18	Pancreatic Neoplasms (Pancreatic Cancer) 01/2018 - 10/2002
17	Carcinoma (Carcinomatosis) 02/2024 - 04/2002
14	Neoplasm Metastasis (Metastasis) 01/2020 - 01/2002
9	Non-Muscle Invasive Bladder Neoplasms 12/2023 - 01/2017
8	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 04/2002
8	Breast Neoplasms (Breast Cancer) 01/2017 - 01/2003
6	Hypoxia (Hypoxemia) 01/2021 - 07/2003
6	Adenocarcinoma 07/2012 - 05/2002
5	Multiple Myeloma 01/2012 - 01/2006
4	Transitional Cell Carcinoma 12/2009 - 07/2003
3	Circulating Neoplastic Cells 01/2021 - 01/2013
3	Sarcoma (Soft Tissue Sarcoma) 01/2020 - 09/2004
3	Necrosis 12/2010 - 12/2002
2	Small Cell Carcinoma 01/2021 - 12/2020
2	Carcinoma in Situ 01/2018 - 12/2009
2	Melanoma (Melanoma, Malignant) 12/2012 - 11/2012
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2012 - 09/2004
2	Hematologic Neoplasms (Hematological Malignancy) 01/2012 - 07/2007
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 08/2008 - 07/2007
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2006 - 10/2003
2	Colonic Neoplasms (Colon Cancer) 11/2002 - 01/2002
1	Disease Progression 12/2023

Drug/Important Bio-Agent (IBA)

18	Phenobarbital (Luminal)FDA Link 02/2024 - 02/2014
18	Proteasome InhibitorsIBA 01/2018 - 12/2002
18	Bortezomib (Velcade)FDA Link 01/2018 - 12/2002
15	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 12/2005
13	Biomarkers (Surrogate Marker)IBA 09/2022 - 09/2002
12	ErbB Receptors (EGF Receptor)IBA 09/2022 - 09/2004
12	Messenger RNA (mRNA)IBA 01/2021 - 07/2010
11	DNA (Deoxyribonucleic Acid)IBA 09/2021 - 07/2008
11	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2002
9	Proteasome Endopeptidase Complex (Proteasome)IBA 12/2012 - 12/2002
8	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2009 - 12/2002
7	Phosphotransferases (Kinase)IBA 01/2018 - 11/2005
7	Cadherins (E-Cadherin)IBA 02/2013 - 03/2008
6	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2017
6	Immune Checkpoint InhibitorsIBA 01/2021 - 10/2016
6	Gemcitabine FDA Link 01/2021 - 10/2002
6	NF-kappa B (NF-kB)IBA 12/2008 - 12/2002
6	Gefitinib (Iressa)FDA Link 09/2008 - 09/2004
5	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 01/2003
5	Histone Deacetylase InhibitorsIBA 12/2012 - 04/2006
5	LigandsIBA 12/2006 - 12/2004
5	Docetaxel (Taxotere)FDA Link 08/2006 - 01/2003
5	Interleukin-8 (Interleukin 8)IBA 01/2006 - 07/2003
4	atezolizumabIBA 12/2023 - 10/2016
4	InterferonsIBA 09/2022 - 09/2004
4	AntibodiesIBA 01/2022 - 09/2002
4	Transcription Factors (Transcription Factor)IBA 01/2020 - 12/2002
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 09/2008 - 07/2004
4	Tyrosine Kinase InhibitorsIBA 09/2007 - 11/2005
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2006 - 12/2004
4	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 12/2004 - 09/2003
3	Vinblastine (Vinblastine Sulfate)FDA Link 01/2021 - 02/2014
3	MicroRNAs (MicroRNA)IBA 01/2021 - 12/2016
3	Methotrexate (Mexate)FDA LinkGeneric 01/2021 - 02/2014
3	ClaudinsIBA 01/2018 - 07/2014
3	marizomibIBA 12/2012 - 07/2007
3	Peptides (Polypeptides)IBA 08/2006 - 12/2002
3	EndostatinsIBA 07/2004 - 09/2002
2	Interferon-alpha (Interferon Alfa)IBA 09/2022 - 06/2007
2	Sirolimus (Rapamycin)FDA Link 12/2021 - 01/2021
2	Methylnitrosourea (N-Methyl-N-nitrosourea)IBA 01/2018 - 01/2017
2	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 07/2013 - 01/2013
2	Protein Isoforms (Isoforms)IBA 02/2013 - 08/2008
2	Small Interfering RNA (siRNA)IBA 01/2013 - 04/2006
2	Vorinostat FDA Link 12/2012 - 04/2006
2	Histone Deacetylases (Histone Deacetylase)IBA 12/2012 - 04/2006
2	Taxoids (Taxanes)IBA 05/2012 - 08/2006
2	Growth Factor ReceptorsIBA 02/2011 - 09/2007
2	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 02/2011 - 01/2005
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2009 - 08/2008
2	Monoclonal AntibodiesIBA 09/2007 - 07/2004
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 09/2007 - 08/2006
2	Caspase 8 (Caspase-8)IBA 07/2007 - 06/2005
2	Antineoplastic Agents (Antineoplastics)IBA 01/2006 - 08/2003
2	Dinoprostone (PGE2)FDA Link 11/2005 - 12/2004
2	Semaxinib (SU5416)IBA 01/2005 - 09/2004
2	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2005 - 07/2004
2	CaspasesIBA 09/2004 - 06/2002
2	Angiogenesis InhibitorsIBA 09/2004 - 07/2004
2	Boronic AcidsIBA 03/2004 - 10/2003
2	DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)IBA 01/2004 - 10/2002
2	ATP dependent 26S protease (26S proteasome)IBA 11/2003 - 09/2003
2	InterleukinsIBA 07/2003 - 05/2002
2	2- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- oneIBA 11/2002 - 10/2002
1	durvalumabIBA 01/2023
1	B7-H1 AntigenIBA 01/2022
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 01/2022
1	Neoplasm Antigens (Tumor Antigens)IBA 12/2021

Therapy/Procedure

58	Therapeutics 02/2024 - 09/2002
21	Drug Therapy (Chemotherapy) 01/2024 - 01/2003
13	Neoadjuvant Therapy 01/2024 - 03/2003
10	Cystectomy 12/2023 - 08/2014
8	Immunotherapy 12/2023 - 10/2016
4	Combination Drug Therapy (Combination Chemotherapy) 11/2019 - 03/2004
4	Lasers (Laser) 01/2005 - 12/2002
3	Radiotherapy 01/2023 - 01/2011